POST-ET MYELOFIBROSIS

Clinical trials for POST-ET MYELOFIBROSIS explained in plain language.

Never miss a new study

Get alerted when new POST-ET MYELOFIBROSIS trials appear

Sign up with your email to follow new studies for POST-ET MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug combo aims to tame tough blood cancer when standard treatment Isn't enough

Disease control Recruiting now

This study is for people with myelofibrosis, a serious bone marrow cancer, who are not getting the best results from their current standard medication (ruxolitinib). It will test if adding a new drug called navtemadlin to the standard treatment works better and is safe. About 600…

Matched conditions: POST-ET MYELOFIBROSIS

Phase: PHASE3 • Sponsor: Kartos Therapeutics, Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:34 UTC

POST-ET MYELOFIBROSIS

Get alerted when new POST-ET MYELOFIBROSIS trials appear

New drug combo aims to tame tough blood cancer when standard treatment Isn't enough